Show simple item record

dc.creatorPastina, P
dc.creatorNardone, V
dc.creatorBotta, C
dc.creatorCroci, S
dc.creatorTini, P
dc.creatorBattaglia, G
dc.creatorRicci, V
dc.creatorCusi, MG
dc.creatorGandolfo, C
dc.creatorMisso, G
dc.creatorZappavigna, S
dc.creatorCaraglia, M
dc.creatorGiordano, A
dc.creatorAldinucci, D
dc.creatorTassone, P
dc.creatorTagliaferri, P
dc.creatorPirtoli, L
dc.creatorCorreale, P
dc.date.accessioned2021-01-25T20:54:18Z
dc.date.available2021-01-25T20:54:18Z
dc.date.issued2017-01-01
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4954
dc.identifier.otherFI5ZG (isidoc)
dc.identifier.other29100279 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4972
dc.description.abstract© Pastina et al. Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also elicits systemic immunological events, which sometimes result in the regression of distant metastases (abscopal effect). We have shown the safety and anti-tumor activity of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growthfactor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This regimen, designed on the results of translational studies, showed immune-modulating effects that could trigger and empower the immunological effects associated with tumor irradiation. In order to assess this, we carried out a retrospective analysis in a subset of 69 consecutive patients who received the mPEBev regimen within the BEVA2007 trial. Forty-five of these patients, also received palliative RT of one or more metastatic sites. Statistical analysis (a Log-rank test) revealed a much longer median survival in the group of patients who received RT [mCH vs mCH + RT: 12.1 +/-2.5 (95%CI 3.35-8.6) vs 22.12 +/-4.3 (95%CI 11.9-26.087) months; P=0.015] with no difference in progression-free survival. In particular, their survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) (CD3-CD11b+CD15-CD83+CD80+) [Fold to baseline value (FBV) ≤1 vs > 1: 4+/-5.389 (95%CI,0-14.56) vs 56+/-23.05 (95%CI,10.8-101.2) months; P:0.049)] and central-memory-T-cells (CD3+CD8+CD45RA-CCR7+) [FBV ≤1 vs > 1: 8+/-5.96 (95%CI,0-19.68) vs 31+/-12.3 (95%CI,6.94-55.1) months; P:0.045].
dc.format.extent75904-75913
dc.language.isoen
dc.relation.haspartOncotarget
dc.relation.isreferencedbyImpact Journals, LLC
dc.rightsCC BY
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.subjectimmune-modulation
dc.subjectradiation therapy
dc.subjectmetronomic chemotherapy
dc.subjectNSCLC
dc.subjectretrospective analysis
dc.titleRadiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.18632/oncotarget.20411
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidGiordano, Antonio|0000-0002-5959-016X
dc.date.updated2021-01-25T20:54:13Z
refterms.dateFOA2021-01-25T20:54:18Z


Files in this item

Thumbnail
Name:
Radiotherapy prolongs the survival ...
Size:
1.390Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY
Except where otherwise noted, this item's license is described as CC BY